INDIANAPOLIS—The board of directors of Elevance Health announced the appointment of Amy Schulman as an independent director effective Jan. 12, 2026. Schulman will serve on the Audit and Finance Committees.
“Amy’s record of driving innovation, disciplined investment and strong governance across the health care ecosystem will further strengthen our board’s ability to deliver long-term value for shareholders and meaningful outcomes for consumers,” said Ramey Peru, chair of the Elevance Health board of directors. “Her insight into the intersection of science, technology and patient care makes her an exceptional addition as we continue to advance and expand our services.”
Schulman currently serves as managing partner at Polaris Partners, a venture capital firm managing more than $4 billion across health care and technology investments. She also serves as chair of the board of Alnylam Pharmaceuticals, Inc., a biopharmaceutical company focused on RNA (ribonucleic acid)-based therapeutics, and as a senior lecturer at Harvard Business School, where she teaches leadership and corporate governance. Previously, Schulman held senior executive roles at Pfizer Inc., including executive vice president and general counsel and president of Pfizer Nutrition, overseeing business transformations and strategic acquisitions.
“Amy’s appointment underscores our commitment to a strong, independent board with diverse perspectives and the right balance of experience and innovation,” said Peru. “As Elevance Health continues to execute its strategy, the board’s refreshment process remains central to our mission of improving health outcomes while delivering sustainable, long-term value.”